19 research outputs found
201CD34+ counts after etoposide and cyclophosphamide plus G-CSF mobilization versus G-CSF alone in multiple myeloma patients undergoing autologous transplantation
Get PDF250Program overview: Diseases treated, types of transplants, regimens and outcome in an outpatient blood and marrow transplant program
Get PDF333: Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies and Diseases
Get PDFResults of once daily parenteral busulfan (busulfex®) with cyclophosphamide versus intermittent dosing of busulfan with cyclophosphamide as a preparative regimen for allogeneic transplant recipients with underlying hematological malignancies and diseases
No full text284Development and utilization of a unified strategic business plan for marketing blood and marrow transplant outpatient clinic services the goal is to increase awareness of outpatient transplants and increase referrals
No full textPreliminary Results Of Phase II Trial Of Clofarabine With Parenteral Busulfan (CLO/BU) Followed By Allogeneic Related Or Unrelated Donor Transplantation For The Treatment Of Hematologic Malignancies
No full textPreliminary Results of Phase II Trial of clofarabine With Parenteral Busulfan (CLO/BU) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies
No full text
201CD34+ counts after etoposide and cyclophosphamide plus G-CSF mobilization versus G-CSF alone in multiple myeloma patients undergoing autologous transplantation
No full text
